You have a strange view of semantics. Ashenden has done a lot of work on blood parameters, which were used in pre-gel tests for EPO and laying the foundation for the passport, but as far as I know, he was not involved at all in the gel test for EPO. Approximately 10-15% of the '99 samples that were not Armstrong's tested positive for EPO.
But since this is a thread honoring Ashenden, I want to post abstracts of a couple of his recent papers that demolish the notion that the passport is very effective. Sure would like to see this guy testify at Bert's CAS hearing.
Eur J Appl Physiol. 2011 Feb 20. [Epub ahead of print]
Current markers of the Athlete Blood Passport do not flag microdose EPO doping.
Ashenden M, Gough CE, Garnham A, Gore CJ, Sharpe K.
Source
SIAB Research Consortium, Gold Coast, QLD, Australia,
heyasho@hotmail.com.
Abstract
The Athlete Blood Passport is the most recent tool adopted by anti-doping authorities to detect athletes using performance-enhancing drugs such as recombinant human erythropoietin (rhEPO). This strategy relies on detecting abnormal variations in haematological variables caused by doping, against a background of biological and analytical variability. Ten subjects were given twice weekly intravenous injections of rhEPO for up to 12 weeks. Full blood counts were measured using a Sysmex XE-2100 automated haematology analyser, and total haemoglobin mass via a carbon monoxide rebreathing test. The sensitivity of the passport to flag abnormal deviations in blood values was evaluated using dedicated Athlete Blood Passport software.
Our treatment regimen elicited a 10% increase in total haemoglobin mass equivalent to approximately two bags of reinfused blood. The passport software did not flag any subjects as being suspicious of doping whilst they were receiving rhEPO. We conclude that it is possible for athletes to use rhEPO without eliciting abnormal changes in the blood variables currently monitored by the Athlete Blood Passport.
Scand J Med Sci Sports. 2011 Apr;21(2):235-43. doi: 10.1111/j.1600-0838.2009.01033.x.
Detecting autologous blood transfusions: a comparison of three passport approaches and four blood markers.
Mørkeberg J, Sharpe K, Belhage B, Damsgaard R, Schmidt W, Prommer N, Gore CJ, Ashenden MJ.
Source
Department of Anaesthesiology and Intensive Care, Bispebjerg Hospital, Copenhagen, Denmark.
jakobmoerkeberg@hotmail.com
Abstract
Blood passport has been suggested as an indirect tool to detect various kinds of blood manipulations. Autologous blood transfusions are currently undetectable, and the objective of this study was to examine the sensitivities of different blood markers and blood passport approaches in order to determine the best approach to detect autologous blood transfusions. Twenty-nine subjects were transfused with either one (n=8) or three (n=21) bags of autologous blood. Hemoglobin concentration ([Hb]), percentage of reticulocytes (%ret) and hemoglobin mass (Hbmass) were measured 1 day before reinfusion and six times after reinfusion. The sensitivity and specificity of a novel marker, Hbmr (based on Hbmass and %ret), was evaluated together with [Hb], Hbmass and OFF-hr by different passport methods. Our novel Hbmr marker showed superior sensitivity in detecting the highest dosage of transfused blood, with OFF-hr showing equal or superior sensitivities at lower dosages. Hbmr and OFF-hr showed superior but equal sensitivities from 1 to 4 weeks after transfusion compared with [Hb] and Hbmass, with Hbmass being the only tenable prospect to detect acute transfusions.
Because autologous blood transfusions can be an acute practice with blood withdrawal and reinfusion within a few days, Hbmass seems to be the only option for revealing this practice.